All In MedTech

Device Trial Radar · NCT07626645

Extracorporeal Shock Wave Therapy in Lower Extremity Lymphedema

Efficacy of Extracorporeal Shock Wave Therapy (ESWT) in Lower Extremity Lymphedema: A Randomized Controlled Trial

Last checked: Nov 19, 2026Latest source record: Sep 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

36

Planned (sponsor's estimate)

Start

Sep 1, 2026

Primary completion

Feb 1, 2027

Study completion Feb 1, 2027

Sponsor

Lead sponsor
Gazi UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 4, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Lower extremity lymphedema is a chronic and progressive condition associated with significant functional impairment and reduced quality of life. The current gold-standard treatment is Complex Decongestive Therapy (CDT); however, a substantial proportion of patients continue to experience persistent symptoms during the maintenance phase. This prospective, randomized, double-blind, placebo-controlled clinical trial aims to evaluate the effectiveness of Extracorporeal Shock Wave Therapy (ESWT) as an adjunct to standard CDT maintenance therapy in patients with lower extremity lymphedema. Participants will be randomly allocated to either an active ESWT group or a sham ESWT group, with both groups continuing standard CDT maintenance throughout the study. ESWT will be administered twice weekly for five sessions. Changes in limb volume, skin thickness and subcutaneous tissue thickness assessed by ultrasonography, pain, functional status, and quality of life will be evaluated at baseline, after treatment, and at one-month follow-up.

Conditions

  • Lymphedema, Lower Limb
  • Extracorporeal Shock Wave Therapy
  • Edema Leg
  • Sham-controlled
  • Placebo Control Design

Interventions

  • Extracorporeal Shock Wave Therapy (ESWT)Device

    Radial shock wave therapy will be applied using the EMS Swiss DolorClast® device. Each session will consist of 3,000 impulses delivered at 20 Hz and 2 bar using a 40 mm applicator, targeting fibrotic tissue regions and periinguinal and peripopliteal lymph node areas. ESWT will be administered twice weekly for five sessions

  • Sham Extracorporeal Shock Wave Therapy (Sham ESWT)Device

    Sham ESWT will be applied with identical positioning and session duration as the active ESWT group. Only non-energized impulses will be delivered, ensuring participant blinding. Sham ESWT will be administered twice weekly for five sessions.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Lower Extremity Limb VolumeTime frame: Baseline, immediately after treatment (week 3), and 1-month follow-up

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Gazi University Hospital, Department of Physical Medicine and Rehabilitation, Ankara, 06560

    Ankara, Yenimahalle, Turkey (Türkiye) · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.